Clinical trials: Diabetes Mellitus Type II
Type 2 Diabetes Mellitus
Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus
The study hypothesis is that XOMA 052 is likely to improve glycemic control in subjects with Type 2 Diabetes Mellitus. The purpose of this study is to determine whether XOMA 052 improves glycemic control in subjects on Metformin…
- Trial name
- NCT01144975
- Testing
- XOMA 052
- Where
- Mexico
- Volunteers
- 76 people
- Sponsor
- XOMA (US) LLC
Diabetes Mellitus, Type 2
RESILIENT: A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in Local Clinical Practice in Japan
The purpose of the study is to collect information on how Ryzodeg® works in real world participants. Participants will get Ryzodeg® as prescribed to them by the study doctor. The study will last for about 6 to 8 months.
- Trial name
- RESILIENT (NCT03745157)
- Testing
- Insulin Degludec/Insulin Aspart
- Where
- 29 sites in Japan
- Volunteers
- 246 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Glycemic Response in Persons with Type 2 Diabetes
This will be a randomized crossover design with nutrition supplement interventions.
- Trial name
- NCT04413357
- Testing
- Balanced Nutritional Drink, Diabetes Specific, Balanced Nutritional Drink (DMA), Diabetes Specific, Balanced Nutritional Drink DMB
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Société des Produits Nestlé (SPN)
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus
This trial is conducted in the United States of America (USA). The aim of this trial is to compare the efficacy and safety of two different formulations of insulin degludec (IDeg) in subjects with type 2 diabetes.
- Trial name
- BEGIN™ (NCT01364428)
- Testing
- insulin degludec
- Where
- 45 sites in United States
- Volunteers
- 373 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Phase III Study for Glimepiride + Metformin Hydrochloride (Amaryl M) Slow Release (SR)
Primary: To show the equivalence in terms of efficacy glycated hemoglobin (HbA1c) of glimepiride/metformin slow-release combination tablet (Amaryl M SR 2/500) once daily compared with fixed-dose glimepiride/metformin combination…
- Trial name
- NCT00437554
- Testing
- Glimepiride
- Where
- South Korea
- Volunteers
- 188 people
- Sponsor
- Handok Inc.
Chronic Kidney Disease
A Phase 1, Open-label Safety Study of NKA in Patients With Type 2 Diabetes
The purpose of this study is to determine if selected renal cells, obtained by biopsy from a patient with chronic kidney disease (CKD) and Type 2 Diabetes (i.e., autologous cells) can be safely implanted back into the patient.
- Trial name
- NCT02008851
- Testing
- Neo-kidney augment
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- Tengion
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare two different active treatment regimens of biphasic insulin aspart in subjects with type 2 diabetes.
- Trial name
- NCT01520753
- Testing
- biphasic insulin aspart 70, biphasic insulin aspart 50
- Where
- Denmark
- Volunteers
- 16 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy, safety, tolerability, of Saxagliptin in pediatric patients with type 2 diabetes.
- Trial name
- NCT01204775
- Testing
- Saxagliptin, Metformin IR, Metformin (Active Rescue)
- Where
- 16 sites in United States, Russia and 2 more
- Volunteers
- 26 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus
The purpose of the study is to compare Humalog (Insulin lispro)-recombinant human hyaluronidase (rHuPH20) or Novolog (Insulin aspart)-rHuPH20 to Humalog (Insulin lispro) for the treatment of Type 1 Diabetes Mellitus (T1DM) in…
- Trial name
- NCT01194245
- Testing
- Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart
- Where
- 19 sites in United States
- Volunteers
- 135 people
- Sponsor
- Halozyme Therapeutics
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis
To evaluate the efficacy of fasiglifam 50 mg once daily compared to placebo on glycemic control as measured by glycosilated haemoglobin (HbA1c) over a 16-week treatment period in participants with Type 2 Diabetes Mellitus (T2DM)…
- Trial name
- NCT02015780
- Testing
- Fasiglifam, Antihyperglycemic therapy
- Where
- 30 sites in United States, Bulgaria and 5 more
- Sponsor
- Takeda
Diabetes Mellitus Type 2
A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease
This randomized, double-blind, placebo-controlled parallel arm study will assess efficacy and safety and the effects of taspoglutide on cardiovascular events in patients with inadequately controlled type 2 diabetes mellitus and…
- Trial name
- NCT01018173
- Testing
- taspoglutide
- Where
- 288 sites in United States, Australia and 23 more
- Volunteers
- 2,118 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas
Evaluation of clinical outcomes (specifically cardiovascular outcomes like hospitalization for heart failure), and healthcare cost, and resource utilization, among patients on empagliflozin as an add-on therapy to metformin…
- Trial name
- NCT05102071
- Testing
- empagliflozin, metformin, sulfonylurea
- Where
- United States
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice
This study is to investigate the effects of Fiasp®, a mealtime insulin, in patients with diabetes mellitus. The purpose of this study is to collect information about Fiasp®, which is prescribed to the participants by their…
- Trial name
- NCT03987802
- Testing
- Faster-acting insulin aspart
- Where
- 36 sites in India
- Volunteers
- 42 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Study on Drug Interaction of HRS-1780 Tablets, Henagliflozin Tablets, Metformin Tablets and HRS-7535 Tablets in Healthy Human
This study was designed as a single-center, single-arm, open, fixed-sequence, self-controlled trial in healthy subjects.
- Trial name
- NCT06495931
- Testing
- HRS-1780 tablets, HR20033 tablets, HRS-7535 tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Type 2 Diabetes Mellitus
Bioavailability and Food Effects of HRS-7535 Tablets With Different Formulating Processes in Healthy Subjects
This study was designed as a a single-center, randomized, open, interleaved (3-cycle, 3-sequence) trial. It is planned to enroll 18 healthy subjects.
- Trial name
- NCT06422039
- Testing
- HRS-7535(D) Tablets, HRS-7535(C) Tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Diabetes Mellitus, Type 2
A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM)
The purpose of this study is to evaluate a new formulation of insulin lispro, LY900014, which is a drug that lowers blood sugar.
- Trial name
- NCT03341312
- Testing
- LY900014, Insulin Lispro
- Where
- 2 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Diabetes Type 2, Bariatric Surgery
Magnetic Compression Anastomosis Procedure for Partial Jejuno-ileal Diversion: Evaluating the Feasibility of a Novel Endoscopic Magnetic Metabolic Interventional Therapy
English, Hindi and Gujarati
- Trial name
- 2025/08/EMMIT (NCT07350967)
- Testing
- Magnetic Compression Anastomosis Procedure for Partial Jejuno-ileal Diversion
- Where
- India
- Volunteers
- 5 people
- Sponsor
- iIDEAS Group Holdings Limited
Diabetes Mellitus
A Study of DIA:CONN P8 Smart Insulin Pen With CGM-Based Coaching in Patients With Type 1 or Type 2 Diabetes
A Study of DIA:CONN P8 Smart Insulin Pen With CGM-Based Coaching in Patients With Type 1 or Type 2 Diabetes
- Trial name
- NCT07004153
- Testing
- Smart Coaching Insulin Pen
- Where
- South Korea
- Volunteers
- 152 people
- Sponsor
- G2e Co., Ltd
Diabetes, Diabetes Mellitus, Type 2
A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes
This trial is conducted in Asia. The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart (IDegAsp)) with biphasic insulin aspart (BIAsp) 30 in patients with type 2 diabetes not optimally controlled on…
- Trial name
- BOOST™ (NCT01059812)
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart 30
- Where
- 46 sites in Hong Kong, Japan and 3 more
- Volunteers
- 424 people
- Sponsor
- Novo Nordisk A/S
Diabetic Kidney Disease, Diabetic Nephropathy
A Study in Participants With Diabetic Kidney Disease
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
- Trial name
- NCT01113801
- Testing
- LY2382770
- Where
- 78 sites in United States, Australia and 5 more
- Volunteers
- 417 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.